Precision Biosciences (DTIL) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The study “A Long-term Observational Study in Participants Who Have Received PBGENE-HBV” tracks people with chronic hepatitis B who were treated in a prior Precision BioSciences trial. It aims to follow long-term safety and durability of response, which matters for regulators, payers, and investors watching gene editing in liver disease.
The only product in focus is PBGENE-HBV, an in vivo gene editing therapy designed to target chronic HBV infection. In this follow-up study, no new drug is given; researchers only monitor people who already received PBGENE-HBV.
The study is observational and prospective, so it simply follows patients forward in time and records outcomes. There is no random assignment, no blinding, and no active treatment, which keeps risk low but makes the data more about long-term safety than about direct comparisons.
The planned follow-up period is 15 years, in line with how regulators often treat gene editing programs. The trial is enrolling by invitation, so only people from the earlier PBGENE-HBV study can join, helping Precision build a complete long-term dataset.
The study was first submitted on November 19, 2025, marking the start of formal long-term tracking. The latest update on April 21, 2026 signals that the protocol and status were recently reviewed and suggests steady operational progress.
The long horizon and active status support the view that Precision is serious about de-risking PBGENE-HBV, which can be a positive signal for DTIL holders. Fresh safety and durability data over time may affect sentiment toward gene editing peers working in liver disease and HBV, and may influence partnership or buyout discussions across the space.
The study remains active and updated, and investors can find further details on the ClinicalTrials portal under identifier NCT07254208.
To learn more about DTIL’s potential, visit the Precision Biosciences drug pipeline page.